Inspira Technologies Oxy B.H.N. Ltd. (IINN)

Inspira Technologies Oxy B.H.N. Ltd. (IINN) Healthcare & Pipeline Overview

Inspira Technologies Oxy B.H.N. Ltd. develops and manufactures respiratory support technology, notably the ART system, aiming to reduce the need for invasive mechanical ventilation. The company operates within the medical device sector, focusing on innovative solutions for respiratory failure and enhanced patient outcomes.

What Is the Investment Thesis for IINN?

Inspira Technologies presents a focused investment opportunity within the medical device sector, centered on its ART system as a potential disruptor in respiratory care. The company's value proposition lies in offering a less invasive alternative to mechanical ventilation, which could reduce patient complications and healthcare costs. Key value drivers include successful clinical trials demonstrating the efficacy and safety of the ART system, regulatory approvals from bodies like the FDA and EMA, and strategic partnerships with hospitals and healthcare providers for market penetration. A potential catalyst is the expansion of ART system applications to various respiratory conditions beyond the initial target. However, the company faces risks associated with the regulatory approval process, competition from established medical device companies, and the need for significant capital to fund ongoing research, development, and commercialization efforts. With a market capitalization of $38.77M and a high beta of 2.33, Inspira Technologies exhibits significant volatility and speculative potential.

Based on FMP financials and quantitative analysis

IINN Key Highlights

• Inspira Technologies focuses on the development of the ART system, a potential alternative to invasive mechanical ventilation.
• The company's gross margin stands at 0.7%, indicating a need for improved cost efficiency as the company scales.
• Inspira Technologies operates in the medical device industry, targeting a significant unmet need in respiratory care.
• The company's lead product, the ART system, aims to provide a less invasive method of blood oxygenation.
• Inspira Technologies is based in Israel, allowing access to a growing medical technology hub.

Who Are IINN's Competitors?

IINN is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.

AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance

What Are IINN's Key Strengths?

• Innovative ART system technology.
• Potential to reduce complications associated with mechanical ventilation.
• Focus on a significant unmet need in respiratory care.
• Strong intellectual property portfolio.

What Are IINN's Weaknesses?

• Limited commercialization experience.
• High dependence on the success of the ART system.
• Negative profit margin.
• Small number of employees.

What Could Drive IINN Stock Higher?

• Completion of ongoing clinical trials for the ART system, expected within the next 12-18 months.
• Submission of regulatory filings to the FDA and EMA within the next 12 months.
• Strategic partnerships with hospitals and healthcare providers to facilitate ART system adoption.
• Expansion of ART system applications to various respiratory conditions.

What Are the Key Risks for IINN?

• Financial-distress signal — its Altman Z-Score of -20.85 sits in the distress zone (elevated bankruptcy risk).
• Weak fundamentals — a Piotroski F-Score of 3/9 flags soft profitability, leverage or efficiency.
• Delays in regulatory approvals for the ART system.
• Competition from established medical device companies with greater resources.
• Unfavorable clinical trial results for the ART system.
• Need for significant capital to fund ongoing research, development, and commercialization efforts.
• Reimbursement challenges from healthcare payers for the ART system.

What Are the Growth Opportunities for IINN?

• Expansion of ART System Applications: Inspira Technologies has the opportunity to expand the application of its ART system beyond its initial target of respiratory failure. This could include treating patients with chronic obstructive pulmonary disease (COPD), acute respiratory distress syndrome (ARDS), and other respiratory conditions. The market for respiratory devices is projected to grow, driven by the increasing prevalence of these diseases. Successful clinical trials demonstrating the efficacy of the ART system in these additional applications could significantly increase its market potential. Timeline: Ongoing clinical trials with results expected within the next 12-24 months.
• Strategic Partnerships with Hospitals and Healthcare Providers: Forming strategic partnerships with hospitals and healthcare providers is crucial for the successful commercialization of the ART system. These partnerships can facilitate the adoption of the technology, provide access to patient populations, and generate valuable clinical data. Collaborations with leading medical centers can also enhance the credibility and visibility of the ART system. The medical device market is heavily influenced by hospital purchasing decisions, making these partnerships essential. Timeline: Ongoing efforts to establish partnerships, with potential agreements expected within the next 6-18 months.
• Regulatory Approvals in Key Markets: Obtaining regulatory approvals from bodies like the FDA in the United States and the EMA in Europe is essential for expanding the market reach of the ART system. These approvals validate the safety and efficacy of the technology and allow for its commercialization in major healthcare markets. The regulatory approval process can be lengthy and costly, but it is a critical step in bringing the ART system to patients worldwide. Timeline: Anticipated FDA and EMA submissions within the next 12 months, with potential approvals within 24-36 months.
• Development of Next-Generation Respiratory Support Technologies: Inspira Technologies can leverage its expertise in respiratory care to develop next-generation technologies that address unmet needs in the market. This could include developing more advanced versions of the ART system, exploring new methods of blood oxygenation, or creating integrated respiratory monitoring and management solutions. Innovation is key to maintaining a competitive edge in the medical device industry. Timeline: Ongoing research and development efforts, with potential new product launches within the next 3-5 years.
• Geographic Expansion into Emerging Markets: Expanding into emerging markets such as Asia and Latin America presents a significant growth opportunity for Inspira Technologies. These markets have a growing demand for advanced medical technologies and a large patient population with respiratory diseases. Adapting the ART system to meet the specific needs of these markets and establishing distribution networks are crucial for success. Timeline: Initial market assessments and regulatory filings within the next 18-24 months, with potential commercial launches within 3-5 years.

What Opportunities Does IINN Have?

• Expansion into new respiratory indications.
• Strategic partnerships with hospitals and healthcare providers.
• Regulatory approvals in key markets.
• Development of next-generation respiratory support technologies.

What Threats Does IINN Face?

• Competition from established medical device companies.
• Regulatory hurdles and delays.
• Technological obsolescence.
• Reimbursement challenges from healthcare payers.

What Are IINN's Competitive Advantages?

• Proprietary ART system technology.
• Patents protecting key innovations.
• Potential for strong clinical data supporting efficacy and safety.
• First-mover advantage in the minimally invasive respiratory support market.

What Does IINN Do?

Inspira Technologies Oxy B.H.N. Ltd., established in 2018 and based in Ra'annana, Israel, is a specialty medical device company focused on revolutionizing respiratory care. Formerly known as Insense Medical Ltd. until July 2020, the company is dedicated to the research, development, manufacture, and marketing of innovative respiratory support technology. Their flagship product, the augmented respiration technology (ART) system, is designed to provide a less invasive alternative to traditional mechanical ventilation (MV) for patients suffering from respiratory failure. The ART system utilizes a minimally invasive, portable dual lumen cannula inserted into the jugular vein, employing extra-corporeal direct blood oxygenation to elevate and stabilize declining oxygen saturation levels. This technology aims to improve patient outcomes by reducing the risks associated with invasive MV, such as ventilator-induced lung injury and infections. Inspira Technologies is committed to advancing respiratory care through innovative solutions that enhance patient comfort and recovery, positioning itself as a key player in the medical device industry with a focus on respiratory support.

What Products and Services Does IINN Offer?

• Develops the ART (Augmented Respiration Technology) system.
• Focuses on creating alternatives to invasive mechanical ventilation.
• Manufactures minimally invasive, portable dual lumen cannulas.
• Utilizes extra-corporeal direct blood oxygenation.
• Aims to elevate and stabilize declining oxygen saturation levels.
• Researches and markets respiratory support technology.

How Does IINN Make Money?

• Develops and patents respiratory support technology.
• Manufactures and sells the ART system and related components.
• Generates revenue through direct sales to hospitals and healthcare providers.
• Potentially offers service and maintenance contracts for the ART system.

What Industry Does IINN Operate In?

Inspira Technologies operates within the medical device industry, specifically targeting the respiratory care market. This market is driven by the increasing prevalence of respiratory diseases, technological advancements in medical devices, and the growing demand for less invasive treatment options. The competitive landscape includes established medical device companies offering traditional mechanical ventilators and other respiratory support systems. Inspira Technologies aims to differentiate itself through its ART system, which offers a minimally invasive alternative to conventional ventilation, potentially reducing complications and improving patient outcomes. The global respiratory care devices market is projected to reach significant growth in the coming years, driven by factors such as aging populations and increasing healthcare expenditure.

Who Are IINN's Key Customers?

• Hospitals and medical centers.
• Intensive care units (ICUs).
• Respiratory therapists.
• Patients requiring respiratory support.

IINN Valuation & Market Position

Relative to its peer group, IINN's quantitative score of 46/100 is below the peer average of 58/100.

F-Score 3/9Financial Health

Inspira Technologies Oxy B.H.N. Ltd.'s Piotroski F-Score is 3/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny. Its Altman Z-Score of -20.85 places it in the distress zone, a signal of elevated financial risk.

FY2026 estForward Outlook

Wall Street analysts project Inspira Technologies Oxy B.H.N. Ltd. revenue of about $48.0M for fiscal 2026, with EPS near $0.10.

IINN Financials

IINN Latest News

IINN Analyst Consensus

IINN MoonshotScore

IINN Healthcare Stock FAQ

Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.

Official Resources